Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …

PD1 was originally discovered in 1992 as a molecule associated with activation-induced cell
death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding …

The tumor microenvironment (TME) is a complex and ever-changing “rogue organ”
composed of its own blood supply, lymphatic and nervous systems, stroma, immune cells …

Immunotherapy has become a key therapeutic strategy in the treatment of many cancers. As
a result, research efforts have been aimed at understanding mechanisms of resistance to …

Breast cancer heterogeneity determines cancer progression, treatment effects, and
prognosis. However, the precise mechanism for this heterogeneity remains unknown owing …

As a promising alternative platform for cellular immunotherapy, natural killer cells (NK) have
recently gained attention as an important type of innate immune regulatory cell. NK cells can …

An innovative and generic CRISPR/Cas12a-driven photoelectrochemical (PEC) biosensing
platform was developed for screening of microRNA-21 (miR-21) by coupling with target …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …